Bernardo Pereira Moreira

Dr. Bernardo Pereira Moreira

JLU Giessen
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2017 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
Bernardo Pereira MoreiraBernardo Pereira Moreira
Bernardo Pereira Moreira
CFCarol K. Fonseca
Carol K. Fonseca
THTansy Hammarton
Tansy Hammarton
MBMunira Baqui
Munira Baqui
The flagellum and flagellum attachment zone (FAZ) are important cytoskeletal structures in trypanosomatids, being required for motility, cell division and cell morphogenesis. Trypanosomatid cytoskeletons contain abundant high molecular mass proteins (HMMPs), but many of their biological functions are still unclear. Here, we report the characterization of the giant FAZ protein, FAZ10, in Trypanosoma brucei, which, using immunoelectron microscopy, we show localizes to the intermembrane staples in the FAZ intracellular domain. Our data show that FAZ10 is a giant cytoskeletal protein essential for normal growth and morphology in both procyclic and bloodstream parasite life cycle stages, with its depletion leading to defects in cell morphogenesis, flagellum attachment, and kinetoplast and nucleus positioning. We show that the flagellum attachment defects are probably brought about by reduced tethering of the proximal domain of the paraflagellar rod to the FAZ filament. Further, FAZ10 depletion also reduces abundance of FAZ flagellum domain protein, ClpGM6. Moreover, ablation of FAZ10 impaired the timing and placement of the cleavage furrow during cytokinesis, resulting in premature or asymmetrical cell division.

19 February 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Bernardo Pereira MoreiraBernardo Pereira Moreira
Bernardo Pereira Moreira
MWMichael H. W. Weber
Michael H. W. Weber
SHSimone Haeberlein
Simone Haeberlein
AMAnnika S. Mokosch
Annika S. Mokosch
BSBernhard Spengler
Bernhard Spengler
FFFranco Falcone
Franco Falcone
Schistosomiasis is a neglected tropical disease affecting more than 200 million people worldwide. Chemotherapy relies on one single drug, praziquantel, which is safe but ineffective at killing larval stages of this parasite. Furthermore, concerns have been expressed about the rise in resistance against this drug. In the absence of an antischistosomal vaccine, it is, therefore, necessary to develop new drugs against the different species of schistosomes. Protein kinases are important molecules involved in key cellular processes such as signaling, growth, and differentiation. The kinome of schistosomes has been studied and the suitability of schistosomal protein kinases as targets demonstrated by RNA interference studies. Although protein kinase inhibitors are mostly used in cancer therapy, e.g., for the treatment of chronic myeloid leukemia or melanoma, they are now being increasingly explored for the treatment of non-oncological conditions, including schistosomiasis. Here, we discuss the various approaches including screening of natural and synthetic compounds, de novo drug development, and drug repurposing in the context of the search for protein kinase inhibitors against schistosomiasis. We discuss the status quo of the development of kinase inhibitors against schistosomal serine/threonine kinases such as polo-like kinases (PLKs) and mitogen-activated protein kinases (MAP kinases), as well as protein tyrosine kinases (PTKs).

1 December 2016 in Tuberculosis
Verified
Journal Article
Closed access
TMThiago Malardo
Thiago Malardo
LGLuiz Gustavo Gardinassi
Luiz Gustavo Gardinassi
Bernardo Pereira MoreiraBernardo Pereira Moreira
Bernardo Pereira Moreira
ÉPÉverton Padilha
Éverton Padilha
JLJúlio César Cetrulo Lorenzi
Júlio César Cetrulo Lorenzi
ACArlete Aparecida Martins Coelho-Castelo
Arlete Aparecida Martins Coelho-Castelo

16 April 2020 in ACS Omega
Verified
Journal Article
Open access
Bernardo Pereira MoreiraBernardo Pereira Moreira
Bernardo Pereira Moreira
TATom Armstrong
Tom Armstrong
IBIzabella Cristina Andrade Batista
Izabella Cristina Andrade Batista
NTNaiara Clemente Tavares
Naiara Clemente Tavares
CPCamilla Valente Pires
Camilla Valente Pires
LDLodewijk V. Dekker
Lodewijk V. Dekker
The screening of compound libraries to identify small-molecule modulators of specific biological targets is crucial in the process for the discovery of novel therapeutics and molecular probes. Considering the need for simple single-tool assay technologies with which one could monitor “all” kinases, we developed a fluorescence polarization (FP)-based assay to monitor the binding capabilities of protein kinases to ATP. We used BODIPY ATP-y-S as a probe to measure the shift in the polarization of a light beam when passed through the sample. We were able to optimize the assay using commercial Protein Kinase A (PKA) and H7 efficiently inhibited the binding of the probe when added to the reaction. Furthermore, we were able to employ the assay in a high-throughput fashion and validate the screening of a set of small molecules predicted to dock into the ATP-binding site of PKA. This will be useful to screen larger libraries of compounds that may target protein kinases by blocking ATP binding.

25 August 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
PPPrema Subbarayal Prakash
Prema Subbarayal Prakash
NBNafal J. S. Barwary
Nafal J. S. Barwary
MWMichael H. W. Weber
Michael H. W. Weber
DWDaniel Wan
Daniel Wan
ICIvan Conejeros
Ivan Conejeros
FFFranco Falcone
Franco Falcone
Rat basophilic leukaemia (RBL) cells have been used for decades as a model of high-affinity Immunoglobulin E (IgE) receptor (FcεRI) signalling. Here, we describe the generation and use of huNPY-mRFP, a new humanised fluorescent IgE reporter cell line. Fusion of Neuropeptide Y (NPY) with monomeric red fluorescent protein (mRFP) results in targeting of fluorescence to the granules and its fast release into the supernatant upon IgE-dependent stimulation. Following overnight sensitisation with serum, optimal release of fluorescence upon dose-dependent stimulation with allergen-containing extracts could be measured after 45 min, without cell lysis or addition of any reagents. Five substitutions (D194A, K212A, K216A, K226A, and K230A) were introduced into the FcεRIα cDNA used for transfection, which resulted in the removal of known endoplasmic reticulum retention signals and high surface expression of human FcεRIα* in huNPY-mRFP cells (where * denotes the penta-substituted variant), comparable to the ~500,000 FcεRIα molecules per cell in the RS-ATL8 humanised luciferase reporter, which is a human FcεRIα/FcεRIγ double transfectant. The huNPY-mRFP reporter was used to demonstrate engagement of specific IgE in sera of Echinococcus granulosus-infected individuals by E. granulosus elongation factor EgEF-1β and, to a lesser extent, by EgEF-1δ, which had been previously described as IgE-immunoreactive EgEF-1β/δ.

2 August 2025 in Liver International
Verified
Journal Article
Open access
FSFrederik Stettler
Frederik Stettler
LKLukas Knedla
Lukas Knedla
MHMaximilian Hagen
Maximilian Hagen
VBVerena von Bülow
Verena von Bülow
HMHeike Müller
Heike Müller
MRMartin Roderfeld
Martin Roderfeld
Background and Aims: Schistosomiasis is a neglected tropical disease affecting more than 250 million people worldwide. Eggs of the parasitic helminth S. mansoni cause major morbidity in the liver, spleen and intestine. Of note, egg‐released soluble antigens (SEA) induce the transcription factor c‐Jun in hepatocytes, promoting hepatocellular cell cycle activity, proliferation and apoptosis. In this study, we analysed the hepatic effect of pharmacological inhibition of c‐Jun N‐terminal kinase (JNK) after infection with S. mansoni . The JNK inhibitor SP600125 was chosen because it had no effect on schistosome viability. Methods: Eight‐week‐old male mice were infected with 100 cercariae (♂ + ♀) and 6 weeks later treated with SP600125 via a subcutaneously implanted osmotic pump over 3 weeks. Hepatic damage, inflammation, fibrosis and metabolic aspects were analysed in liver and spleen tissue as well as in serum samples. Results: JNK inhibitor‐treated mice infected with S. mansoni showed a parasite‐induced elevation of serum aminotransferases. Hepatic inflammation, the activation of hepatic stellate cells and metabolic exhaustion were observed in infected control mice. Additional SP600125 application almost doubled enhanced transaminases, hepatic cytokine expression, inflammation, necrosis, as well as HSC activation, and decreased glycogen stores to a minimum. Conclusions: Our findings suggest a protective role of JNK/c‐Jun‐signalling in hepatic inflammation, hepatic stellate cell activation, and metabolic exhaustion during S. mansoni infection.